Remote Monitoring of Multiple COVID-19 Symptoms: A New Era in Access Screening?

Temperature screening is insufficient to detect COVID-19 infection. Emerging technology is enabling contactless multi-symptom screening with high sensitivity.

LONDON, UNITED KINGDOM, February 8, 2021 /EINPresswire.com/ -- Since the outbreak of COVID-19 in December 2020, employee and customer screening for COVID-19 symptoms has become commonplace and, indeed, mandatory in many countries around the world. This screening has typically consisted of answering a simple questionnaire and/or having one's temperature taken. However, experts emphasize that temperature-based screening alone is insufficient to detect COVID-19 infection.1–4 This gap, along with the need for remote monitoring of COVID-19 patients, has created a niche for new technology that can assess multiple COVID-19 symptoms simultaneously without requiring an operator or any physical contact.5–8

An elevated temperature does not necessarily imply infection with COVID-19, and inversely, a person can have COVID-19 but not have a fever or any other visible symptoms of infection. In fact, temperature screening alone may miss more than 50% of persons with COVID-19.1–4

With this in mind, screening for COVID-19 should ideally assess multiple symptoms of infection. Besides an elevated temperature, other vital signs should be measured such as the heart rate,
respiratory rate, oxygen saturation level, and blood pressure. When the human body is fighting an infection, there are measurable changes in these vital signs. The resting heart rate may increase and become more variable, breathing may become more rapid, body temperature may rise, and blood pressure and oxygen saturation may drop.9,10

Addressing this need for multi-symptom COVID-19 screening are recently launched systems such as Modcon's VsScan developed in the United Kingdom, Neteera Technologies' Neteera 1.0 developed in Israel, Soter Technologies’ SymptomSenseTM Medical Evaluation Gateway in the USA, and the ongoing Alba Vital Scan project of Alba Medical Sciences in partnership with the NHS in Scotland. These systems will likely prove particularly useful for COVID-19 screening at places where there is high foot traffic or increased risk of infection, such as airports, hospitals, border posts, shopping malls, industrial complexes, stadiums, places of education, and care homes.

Multi-symptom analyzers work by being placed next to turnstiles at points of access control. The person steps onto the demarcated spot in front of the analyzer, and once the remote scan is complete, it generates a score that determines whether the individual can continue as normal (e.g., using the “fast” route for access) or whether they need to enter the “slow” route for further assessment. Systems such as Modcon’s VsScan can perform multi-symptom assessment within a few seconds with the accuracy of standard medical devices. The company is currently undergoing FDA certification to utilize VsScan as a first-tier contactless medical diagnostic to help hospitals fight COVID-19.

This technology allows visitors to be rapidly scanned without any physical contact and without any need for assigning personnel to this high-risk task. Studies have shown that contactless vital sign measurement can achieve a performance similar to that of conventional contact medical devices (e.g., thermometer or ECG) and higher sensitivity than temperature-based screening alone.5,11,12

Are multi-symptom analyzers likely to become a necessary tool for businesses and organizations in the future? Unfortunately, experts are warning that because of factors such as human encroachment on natural habitats and increasing globalization, emerging infectious diseases such as COVID-19 are not to be considered an anomaly—instead, global epidemiological trends indicate that pathogens (mostly viruses) are more frequently being transferred from reservoirs such as wildlife to human populations.13,14 It may be prudent, therefore, to be ahead of the
curve by widely implementing technologies that can be used to detect both COVID-19 and infections in general.

References

Natasha Beeton-Kempen, Ph.D.
Science consultant and writer
email us here

This press release can be viewed online at: https://www.einpresswire.com/article/535329361

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2021 IPD Group, Inc. All Right Reserved.